Učitavanje...
Visual Acuity Improvement when Switching from Ranibizumab to Aflibercept is Not Sustained
PURPOSE: To assess whether visual benefits exist in switching to aflibercept in patients who have been chronically treated with ranibizumab for neovascular age-related macular degeneration (nvAMD). METHODS: We performed a multicenter, national electronic medical record database study. Patients under...
Spremljeno u:
| Izdano u: | Retina |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5636644/ https://ncbi.nlm.nih.gov/pubmed/28406859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IAE.0000000000001637 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|